ClinicalTrials.gg
RecruitingNCT07855276Updated Nov 10, 2026

A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

A Phase 1 interventional study of LOU064 and Placebo in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Now RecruitingFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Planned enrollment
10th of 10
30 · median 545
Started
2026
with 4 others
Phase 1
Only one
of the 21
Primary completion
2027-11
later than 9 of 13 live
Registered
21st of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 10th largest by planned enrollment of the 10 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 1, reaches primary completion later than 9 of the 13 other live ones, and was the 21st registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.

Read the detailed description

This is a Phase 1, interventional, multicenter, randomized, double-blind, parallel group, placebo-controlled, exploratory study to evaluate the MoA of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa.

The total duration of the study is 24 weeks and consists of Screening (up to 4 weeks), Treatment (16 weeks, double-blind treatment with remibrutinib or placebo), and Follow-up (treatment-free follow-up for 4 weeks) periods.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • BTK inhibitor
  • hidradenitis suppurativa
  • sHiSCR
  • remibrutinib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male and female participants ≥ 18 years to 65 years of age at the time of signing of the forms (ICF).
  • Diagnosis of HS based on clinical history and physical examination for at least 6 months prior to Day 1.
  • Participants with moderate to severe HS at Day 1 defined as:
  • A total of at least 5 abscesses and inflammatory nodules (AN), i.e. abscesses and/or inflammatory nodules
  • Inflammatory lesions should affect at least 2 distinct anatomic areas (e.g., left and right axillae).
  • At least 1 chronic lesion, which is defined by the presence of a draining tunnel and further meeting criteria as defined in the laboratory manual.

Key Exclusion Criteria:

  • Presence of more than 20 fistulae/tunnels (both draining and non-draining) in total at baseline.
  • Use of other drugs within 5 half-lives, or within 30 days (for small molecules) prior to randomization, or until the pharmacodynamic effect has returned to baseline (for biologics), whichever is longer.
  • Previous exposure to remibrutinib or other BTK inhibitors.
  • Previous exposure to investigational Janus Kinase (JAK) inhibitors.
  • Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include and are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected (HIV) infection. Should it be required by local regulations and/or considered appropriate by the investigator, an HIV test can be performed to confirm eligibility.
  • Significant bleeding risk or coagulation disorders.
  • History or current hepatic disease (moderate to severe Hepatic Impairment (HI) as per classification), including but not limited to, acute or chronic hepatitis (with the exception of or C - see respective exclusion criterion above), cirrhosis or hepatic failure or (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x (ULN) or (INR) of more than 1.5 at Screening.
  • Women of , defined as all women physiologically capable of becoming pregnant from menarche until becoming , unless they have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In the case of oophorectomy alone, the reproductive status of the woman needs to have been confirmed by follow-up hormone level assessment. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., hormonal profile confirming menopause and/or age-appropriate history of vasomotor symptoms). WOCBP are excluded unless they are using highly effective methods of (failure rate \< 1% per year) while taking study treatment and for 7 days after stopping study treatment. Highly effective contraception methods.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    LOU064

    Participants will receive remibrutinib during treatment period.

    Drug: LOU064

  • Placebo comparator
    Placebo

    Participants will receive matching placebo during treatment period.

    Drug: Placebo

Interventions

  • DrugLOU064

    Remibrutinib

    Also known as: remibrutinib

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Fold change from baseline in auto-antibodies

    To evaluate the effect of remibrutinib compared with placebo.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs, including changes in vital signs and laboratory values qualifying and reported as AEs.

    Time frame: Up to Week 20

07

Study locations

2 of 2 sites recruiting
  • University Clinical Trials
    San Diego, California 92123, United States
    Recruiting
    • Carlos Vega · Contactcarlos@univct.com · +1 858 278 8470
    • Walter K Nahm · Principal investigator
  • Apex Clinical Research Center LLC
    Mayfield Heights, Ohio 44124, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Nov 2027, 13 months after the start.

Of 20 phase 1 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 13 months is below that.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jun 2028 → Nov 2027, last on Nov 10, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Jul 2028 → Dec 2027, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Oct 29, 2026
Primary completionEst.
Nov 29, 2027was Jun 2028
CompletionEst.
Dec 27, 2027was Jul 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • Apex Clinical Research Center LLC · Mayfield Heights, United States
  • University Clinical Trials · San Diego, United States
across 2 updates, Oct 16, 2026 – Nov 10, 2026
Start date
Oct 14, 2026→Oct 29, 2026 (actual)
moved 2 times, Oct 16, 2026 – Nov 10, 2026
Primary completion
Jun 19, 2028→Nov 29, 2027
moved 2 times, Oct 16, 2026 – Nov 10, 2026
Study completion
Jul 17, 2028→Dec 27, 2027
moved 2 times, Oct 16, 2026 – Nov 10, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Nov 10, 2026
    1 site added
    Show site
    • University Clinical Trials · San Diego, United States
    Start date Oct 15, 2026→Oct 29, 2026 (now actual)
    Primary completion Dec 21, 2027→Nov 29, 2027
    Study completion Jan 18, 2028→Dec 27, 2027
    + 1 other change: verification date
  2. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Apex Clinical Research Center LLC · Mayfield Heights, United States
    Start date Oct 14, 2026→Oct 15, 2026
    Primary completion Jun 19, 2028→Dec 21, 2027
    Study completion Jul 17, 2028→Jan 18, 2028
    + 1 other change: verification date
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855276
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 29, 2026
Primary completion
Nov 29, 2027 (estimated)
Completion
Dec 27, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion